8-K: The Joint Corp. Reports 14% Revenue Growth in Q4 2024, Focuses on Franchising and Profitability

The Joint Corp. announces a 14% increase in Q4 2024 revenue and outlines strategic initiatives to strengthen its core business and expand its franchise model.

Summary

• The Joint Corp. reported a 14% increase in revenue for Q4 2024, reaching $14.4 million.
• Net income from continuing operations was $986,000, a significant improvement from a $10.2 million loss in Q4 2023.
• System-wide sales increased by 9% to $145.2 million in Q4 2024.
• System-wide comp sales grew by 6%, up from 4% in Q3 2024.
• Adjusted EBITDA for Q4 2024 was $3.3 million.
• For the full year 2024, revenue grew by 10% to $51.9 million.
• Net loss from continuing operations improved to $1.5 million, compared to $10.8 million in 2023.
• System-wide sales for 2024 increased by 9% to $530.3 million.
• The company performed 14.7 million patient visits in 2024, up from 13.6 million in 2023.
• The Joint Corp. treated 957,000 new patients in 2024, compared to 932,000 in 2023.
• The company expects system-wide sales between $550 million and $570 million in 2025.
• System-wide comp sales are projected to grow in the mid-single digits in 2025.
• Consolidated Adjusted EBITDA is expected to be between $10.0 and $11.5 million in 2025.
• The company anticipates opening 30 to 40 new franchised clinics in 2025, excluding refranchised clinics.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue and system-wide sales show positive growth, there are concerns about decreased profitability and future growth projections. The company's strategic initiatives and focus on franchising are positive, but risks related to staffing, inflation, and potential refranchising challenges temper the overall outlook.

Positives

• Revenue from continuing operations increased by 14% in Q4 2024.
• Net income from continuing operations improved significantly in Q4 2024.
• System-wide sales and comp sales showed positive growth in Q4 2024.
• Full-year revenue and system-wide sales increased by 10% and 9% respectively.
• Net loss from continuing operations improved for the full year 2024.
• The company has immediate access to $20 million through February 2027 via a credit facility.
• The company performed 14.7 million patient visits in 2024, up from 13.6 million in 2023.
• The company treated 957,000 new patients in 2024, compared to 932,000 in 2023.

Negatives

• Loss from discontinued operations was $3.7 million in Q4 2024, compared to $863,000 in Q4 2023.
• Adjusted EBITDA for continuing operations decreased from $4.5 million to $2.4 million year over year.
• The company reported a net loss of $8.5 million for the full year 2024.
• New franchised clinic openings are expected to decrease from 57 in 2024 to between 30 and 40 in 2025.
• Consolidated Adjusted EBITDA is expected to be between $10.0 and $11.5 million in 2025, compared to $11.4 million in 2024.

Risks

• The company's inability to identify and recruit enough qualified chiropractors and other personnel to staff clinics.
• Inflation, which has increased costs and could negatively impact the business.
• Failure to profitably operate company-owned or managed clinics.
• Failure to refranchise as planned.
• Short-selling strategies and negative opinions posted on the internet, which could drive down the market price of the common stock and result in class action lawsuits.
• Failure to remediate future material weaknesses in internal control over financial reporting.

Future Outlook

The company expects system-wide sales between $550 million and $570 million in 2025, system-wide comp sales to grow in the mid-single digits, and consolidated Adjusted EBITDA to be between $10.0 and $11.5 million. New franchised clinic openings are expected to be between 30 and 40, excluding refranchised clinics.

Management Comments

• Sanjiv Razdan, President and Chief Executive Officer of The Joint Corp., said, 'In 2025, we are focused on bolstering our position as the leading chiropractic care provider, becoming a world class, pure play franchisor.'
• Sanjiv Razdan also stated, 'We have begun executing initiatives to strengthen our core, reignite growth and improve both clinic and company level profitability.'
• Sanjiv Razdan noted, 'Already, in the fourth quarter of 2024, we have growing momentum with system-wide sales increasing 9% compared to the fourth quarter of 2023.'
• Sanjiv Razdan added, 'Driving success, in 2026, we expect to grow net new clinic openings, system-wide sales, comp sales and Adjusted EBITDA. I am confident we will emerge as a stronger company.'

Industry Context

The Joint Corp. is positioning itself as a leader in the chiropractic industry by focusing on a franchise model and expanding access to affordable care. The company's growth strategy aligns with the increasing demand for accessible health and wellness services.

Comparison to Industry Standards

• The Joint Corp.'s focus on franchising is similar to companies like Planet Fitness, which have successfully scaled through a franchise model in the fitness industry.
• The company's system-wide sales growth of 9% is comparable to other franchise businesses in the health and wellness sector.
• The Joint Corp.'s emphasis on affordable care aligns with trends in the healthcare industry towards value-based services.
• The company's expansion strategy is similar to companies like Anytime Fitness, which have grown rapidly by offering convenient and accessible services.

Corporate Governance

Stakeholder Impact

• Shareholders may experience increased value if the company successfully executes its strategic initiatives and improves profitability.
• Franchisees may benefit from the company's focus on strengthening clinic economics and reigniting growth.
• Patients may benefit from improved access to affordable chiropractic care.
• Employees may experience increased job security and growth opportunities if the company achieves its goals.

Next Steps

• The company will continue to execute its strategic initiatives to strengthen its core business and expand its franchise model.
• The company will focus on refranchising corporate clinics to enhance profitability.
• The company will initiate dynamic revenue management, enhance digital marketing, and upgrade patient-facing technology to drive revenue growth.
• The company will build infrastructure and test elements to capture new markets and revenue channels.
• The company will focus on growing net new clinic openings, system-wide sales, comp sales, and Adjusted EBITDA in 2026.

Key Dates